Sarcopenia is a reliable predictor of outcomes following radical cystectomy for bladder cancer

Radical cystectomy (RC) with pelvic lymph node dissection, preceded by cisplatin-based neoadjuvant chemotherapy in appropriate patients, remains the gold-standard in the treatment of muscle invasive bladder cancer (MIBC) (1,2). RC is a complex operation performed in an elderly (and sometimes unhealthy) patient population, with significant complication rates (as high as 60%) and perioperative mortality rates (9%) reported at 90-days (3,4).